The ability to target FAP in the stroma of advanced or metastatic FAP-positive cancer with repeated infusions of a humanized antibody (sibrotuzumab) directed against FAP provided additional evidence to inhibit CAF functions in the targeting and therapy of epithelial malignancies (Scott et al., 2003; Jiang et al., 2016). The gene discussed is FAP; the disease is cancer.